Junshi Biosciences, based in Shanghai, China, announced that an Independent Monitoring Committee (IDMC) decided the company’s Phase III JUPITER-02 trial had met the pre-specified primary endpoint at the interim analysis.
https://www.pharmalive.com/wp-content/uploads/2020/09/Junshis-Checkpoint-Inhibitor-Ready-to-Head-to-Regulators-for-Throat-Cancer-BioSpace-9-29-20.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2020-09-29 11:25:302020-09-29 13:05:06Junshi’s Checkpoint Inhibitor Ready to Head to Regulators for Throat Cancer